Bioactive coating composition and methods

• US 6,921,811 B2
• Filed: 07/31/2001
• Issued: 07/26/2005
• Est. Priority Date: 09/22/1998
• Status: Expired due to Term

• Current Assignee: Biosurface Engineering Technologies, Inc. (Ferring Holding SA)
• Original Assignee: Biosurface Engineering Technologies, Inc. (Ferring Holding SA)
• Inventors: Zamora, Paul O., Tsang, Ray, Osaki, Shigemasa
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): Maier, Leigh C.
• Application Number:
  US10/450,309
• Publication Number:
  US 20040161442A1
• Time in Patent Office: 1,456 Days
• Field of Search: 536/21, 514/56, 523/122, 427/2.1, 427/2.13, 604/57, 623/1.42
• US Class Current: 536/21
• CPC Class Codes: A61L 15/28 Polysaccharides or their derivatives A61L15/225 takes precedence
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 17/005 containing a biologically active substance, e.g. a medicament or a biocide
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 33/0011 Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate

Abstract

The present invention provides a bioactive coating composition, method and devices for bodily fluid-contacting surfaces. The coating comprises a complex of Formula II: wherein R₁ is an C_1-18alkyl or C_6-32aryl group, each R₂ is independently selected from the group consisting of C_1-18alkyl and C_6-32aryl, R₃ is N or O, n is a number from 1 to 10, and x in a number from 1 to about 30, directly bound to a heparin-activity molecule via covalent bonding, with one or more bioactive molecules bound to the heparin-activity molecule. The bioactive molecule may be an adhesive molecule such as fibronectin, a growth factor such as basic fibroblast growth factor, or any other bioactive molecule that binds, by any mechanism, to a heparin-activity molecule

Claims

1. A coating composition for contacting surfaces of medical device, said composition comprising a molecule of Formula I:

wherein

R₁ is an C_1-18 alkyl or C_6-32 aryl group,

each R₂ is independently selected from the group consisting of C_1-18 alkyl and C_6-32 aryl

R₃ is N or O,

n is a number from 1 to 10, and

x is a number from 1 to about 30,

bound to a heparin-activity molecule via a covalent bond, thereby forming a silyl-heparin covalent complex, with a bioactive molecule directly bound to the heparin-activity molecule.

2. The composition according to claim 1, wherein the silyl-heparin covalent complex has a disassociation rate from the contacting surface determined by the value of n and x.

3. The composition according to claim 1, wherein the silyl-heparin covalent complex binds to the contacting surfaces via hydrophobic bonding interactions.

4. The composition according to claim 3, wherein the heparin-activity molecule is heparin, heparan sulfate, hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, or a molecule including a mixture of variably sulfated polysaccharide chains composed of repeating units of D-glucosamine and either L-iduronic or D-glucuronic acids, salts of any of the foregoing and derivatives of any of the foregoing.

5. The composition according to claim 1, wherein said bioactive molecule is directly bound to the heparin-activity molecule by affinity complexation.

6. The composition according to claim 1, wherein the silyl-heparin covalent complex comprises [benzyl-bis(dimethylsilylmethyl)]-(N-heparinyl)-carbamate or [benzyl-tris(dimethylsilylmethyl)]-(N-heparinyl)-carbamate.

7. The composition according to claim 1, wherein said bioactive molecule is an adhesive molecule, a growth factor molecule or a therapeutic molecule.

8. The composition according to claim 7, wherein the adhesive molecule is fibronectin, laminin, vitronectin, thrombospondin, gelatin, polylysine, polyornithine, peptide polymers containing adhesive sequences and heparin binding sequences, sulfated complex carbohydrates, dextran sulfate, growth hormones, cytokines, lectins, or peptidic polymers thereof.

9. The composition according to claim 7, wherein the growth factor molecule is fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, hepatocyte growth factor, placental growth factor, insulin-like growth factor, nerve growth factors and neurotrophins, heparin-binding epidermal growth factor, transforming growth factor-β

, bone morphogenetic protein 2, osteogenic protein 1 or keratinocyte growth factor.

10. A medical device with at least one contacting surface for contacting bodily fluids, the surface having coated thereon a coating composition comprising a molecule of Formula I:

wherein

R₁ is an C_1-18 alkyl or C_6-32 aryl group,

each R₂ is independently selected from the group consisting of C_1-18 alkyl and C_6-32 aryl,

R₃ is N or O,

n is a number from 1 to 10, and

x is a number from 1 to about 30,

directly bound to a heparin-activity molecule via covalent bonding, thereby forming a silyl-heparin covalent complex, with a bioactive molecule directly bound to the heparin-activity molecule.

11. The device according to claim 10, wherein the silyl-heparin covalent complex binds to the surface via hydrophobic bonding interactions.

12. The device according to claim 10, wherein the silyl-heparin covalent complex has a disassociation rate from the surface determined by the value of n and x.

13. The device according to claim 10, wherein the heparin-activity molecule is heparin, heparan sulfate, hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, or a molecule including a mixture of variably sulfated polysaccharide chains composed of repeating units of D-glucosamine and either L-iduronic or D-glucuronic acids, salts of any of the foregoing and derivatives of any of the foregoing.

14. The device according to claim 10, wherein said bioactive molecule is directly bound to the heparin-activity molecule by affinity complexation.

15. The device according to claim 10, wherein the silyl-heparin covalent complex comprises [benzyl-bis(dimethylsilylmethyl)]-(N-heparinyl)-carbamate or [benzyl-tris(dimethylsilylmethyl)]-(N-heparinyl)-carbamate.

16. The device according to claim 10, wherein the device is a blood gas exchange device, blood filter, artificial blood vessel, artificial valve, prosthetic, blood shunt, catheter, bone replacement, cartilage replacement, suture, graft, catheter or nerve growth guide.

17. The device according to claim 10, wherein said bioactive molecule is an adhesive molecule, a growth factor molecule or a therapeutic molecule.

18. The device according to claim 17, wherein the adhesive molecule is fibronectin, laminin, vitronectin, thrombospondin, gelatin, polylysine, polyornithine, peptide polymers containing adhesive sequences and heparin binding sequences, sulfated complex carbohydrates, dextran sulfate, growth hormones, cytokines, lectins, or peptidic polymers thereof.

19. The device according to claim 17, wherein the bioactive molecule is an adhesive molecule, whereby the contacting surface is non-thrombogenic and promotes cellular adhesion.

20. The device according to claim 17, wherein the growth factor molecule is fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, hepatocyte growth factor, placental growth factor, insulin-like growth factor, nerve growth factors and neurotrophins, heparin-binding epidermal growth factor, transforming growth factor-β

, bone morphogenetic protein 2, osteogenic protein 1 or keratinocyte growth factor.

21. A method for coating a contacting surface of a medical device with a bioactive coating composition, comprising:

providing a hydrophobic silyl moiety of Formula I

 

wherein

R₁ is an C_1-18 alkyl or C_6-32 aryl group,

each R₂ is independently selected from the group consisting of C_1-18 alkyl and C_6-32 aryl,

R₃ is N or O, and

n is a number from 1 to 10

binding said silyl moiety to a heparin-activity molecule via covalent bonding, wherein x is from 1 to about 30 for each heparin-activity molecule, thereby forming a silyl-heparin complex,

attaching the silyl-heparin complex to the contacting surface by hydrophobic interaction, and

attaching a bioactive molecule to the heparin-activity molecule.

22. The method of claim 21, wherein the silyl-heparin complex has a disassociation rate from the contacting surface determined by the value of n and x.

23. The method of claim 21, wherein the heparin-activity molecule is heparin, heparan sulfate, hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, or a molecule including a mixture of variably sulfated polysaccharide chains composed of repeating units of D-glucosamine and either L-iduronic or D-glucuronic acids, salts of any of the foregoing and derivatives of any of the foregoing.

24. The method of claim 21, wherein the bioactive molecule is attached to the heparin-activity molecule by affinity complexation.

25. The method of claim 21, wherein the silyl-heparin complex comprises [benzyl-bis(dimethylsilylmethyl)]-(N-heparinyl)-carbamate or [benzyl-tris(dimethylsilylmethyl)]-(N-heparinyl)-carbamate.

26. The method of claim 21, wherein the bioactive molecule is an adhesive molecule, whereby the contacting surface is non-thrombogenic and promotes cellular adhesion.

27. The method of claim 21, wherein the bioactive molecule is an adhesive molecule, a growth factor molecule or a therapeutic molecule.

28. The method of claim 27, wherein the adhesive molecule is fibronectin, laminin, vitronectin, thrombospondin, gelatin, polylysine, polyornithine, peptide polymers containing adhesive sequences and heparin binding sequences, sulfated complex carbohydrates, dextran sulfate, growth hormones, cytokines, lectins, or peptidic polymers thereof.

29. The method of claim 27, wherein the growth factor molecule is fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth factor, hepatocyte growth factor, placental growth factor, insulin-like growth factor, nerve growth factors and neurotrophins, heparin-binding epidermal growth factor, transforming growth factor-β

, bone morphogenetic protein 2, osteogenic protein 1 or keratinocyte growth factor.